Table 6.
Efficacy by genotype in recent randomized trials of standard treatments with pegylated interferon-α (PegIFNα) plus ribavirin and the novel regimens based on direct-acting antiviral agents
*Detailed references in Liang and Ghany58 and in the 2014 guidelines of the European Association for the Study of the Liver (EASL).41
†Patients with cirrhosis were included in the trial.
